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Mitotic exit requires the inactivation of
MAD2. Ma and Poon show that MAD2
inactivation in mammalian cells requires
TRIP13 and is stimulated by p31comet.
Moreover, TRIP13-deficient cells
containing only C-MAD2 are unable to
activate the spindle-assembly
checkpoint.
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Biochemical studies have indicated that p31comet
and TRIP13 are critical for inactivating MAD2.
To address unequivocally whether p31comet and
TRIP13 are required for mitotic exit at the cellular
level, their genes were ablated either individually
or together in human cells. Neither p31comet nor
TRIP13 were absolutely required for unperturbed
mitosis. MAD2 inactivation was only partially
impaired in p31comet-deficient cells. In contrast,
TRIP13-deficient cells contained MAD2 exclusively
in the C-MAD2 conformation. Our results indicate
that although p31comet enhanced TRIP13-mediated
MAD2 conversion, it was not absolutely necessary
for the process. Paradoxically, TRIP13-deficient cells
were unable to activate the spindle-assembly check-
point, revealing that cells lacking the ability to inacti-
vate MAD2 were incapable in mounting a checkpoint
response. These results establish a paradigm of
the roles of p31comet and TRIP13 in both checkpoint
activation and inactivation.
INTRODUCTION
Mitotic exit is driven by a ubiquitin ligase called anaphase-pro-
moting complex/cyclosome (APC/C) with its targeting subunit
CDC20 (Pesin and Orr-Weaver, 2008). Unattached kinetochores
or the absence of tension between the paired kinetochores
activates the spindle-assembly checkpoint (SAC), which then
prevents the activation of APC/CCDC20 (Musacchio, 2015).
Hence, the SAC ensures that mitotic exit only occurs after
all the chromosomes have achieved proper bipolar spindle
attachment.
Components of the SAC include a diffusible MCC complex
containing MAD2, BUBR1, BUB3, and CDC20, which facilitates
the inhibition of APC/CCDC20 by MAD2. Binding to APC/CCDC20
requires a change in MAD2 from an open conformation
(O-MAD2) to a more stable closed conformation (C-MAD2) (Yu,
2006). According to a generally accepted model, the C-MAD2
that binds to MAD1 at the kinetochores serves as a template
for converting O-MAD2 into C-MAD2 (De Antoni et al., 2005).
The C-MAD2 then forms the MCC, which in turns may serve as1086 Cell Reports 14, 1086–1099, February 9, 2016 ª2016 The Authoa template for converting more O-MAD2 into C-MAD2. This
model provides a mechanism for autoamplification and propa-
gation of the SAC signal away from the kinetochores.
While significant progress has been made to unravel the
underlying principles of SAC activation, lagging behind is our
knowledge of how the SAC is turned off once the checkpoint
is satisfied. Specifically, how C-MAD2 is converted back to
O-MAD2 is a fundamental but outstanding question. There is
compelling evidence that C-MAD2 is neutralized by binding to
a protein called p31comet (also called MAD2L1BP) in mammalian
cells (Habu et al., 2002). For example, the SAC can be disrupted
by p31comet overexpression, and mitotic exit can be delayed by
p31comet knockdown (Habu et al., 2002; Xia et al., 2004; Chan
et al., 2008a). Crystal structure of p31comet reveals a folding
similar to C-MAD2, suggesting that structural mimicry may be
involved in checkpoint silencing (Yang et al., 2007).
There is evidence that p31comet is involved in the removal of
MAD2 from MCC (Westhorpe et al., 2011). Disassembly of
MCC by p31comet is an ATP-dependent process, involving a
p31comet-interacting protein called TRIP13 (Eytan et al., 2014;
Wang et al., 2014). TRIP13 is an AAA+-ATPase that also func-
tions in meiotic DNA break formation and recombination, check-
point signaling, and chromosome synapsis (Vader, 2015).
Recent structural and in vitro studies indicated that p31comet
acts both as an activator and an adaptor for TRIP13 for promot-
ing C-MAD2 to O-MAD2 conversion (Ye et al., 2015). Whether
p31comet and TRIP13 are indeed responsible for MAD2 inactiva-
tion in the cell remains an important question.
In this study, we investigated the relative role of p31comet and
TRIP13 in SAC inactivation. We showed that both p31comet and
TRIP13 were not essential for unperturbed mitosis in different
cell lines. We also found that C-MAD2 to O-MAD2 conversion
was partially impaired in p31comet-deficient cells and completely
defective in TRIP13-deficient cells. Paradoxically, cells lacking
TRIP13 displayed a relatively short mitosis and were unable to
activate the SAC. We further demonstrate that direct binding of
p31comet to either MAD2 or TRIP13 was sufficient to promote
mitotic exit.
RESULTS
p31comet Is Not Essential for Unperturbed Mitosis
To address unequivocally whether p31comet is required for
mitotic exit, p31comet gene (MAD2L1BP) was disrupted using
TALEN (Figure S1A). Several clones of p31comet-knockoutrs
Figure 1. p31comet Is Not Essential for the
Unperturbed Cell Cycle
(A) Ablation of p31comet in HeLa and HCT116 cells.
The p31comet gene was disrupted in both HeLa and
HCT116 cells using TALEN. The cells were syn-
chronized in mitosis with NOC. Cell-free extracts
were prepared, and the expression of p31comet and
related SAC components was analyzed with
immunoblotting (p31KO, p31comet knockout). Equal
loading of lysates was confirmed by immunoblot-
ting for actin.
(B) Binding of MCC to p31comet is disrupted in
p31KO.Mitotic extracts ofWT and p31KOHeLa cells
prepared as in (A) were subjected to immunopre-
cipitation (IP) using an antiserum against p31comet
or normal rabbit serum (NRS). The immunopre-
cipitates were then analyzed using immuno-
blotting.
(C) Reintroduction of p31comet to p31KO. Parental
HeLa, p31KO, and p31KO with stable expression of
FLAG-p31comet (F-p31) were synchronized and
analyzed as in (A). The arrows indicated the posi-
tions of the endogenous and FLAG-tagged
p31comet.
(D) Knockout of p31comet delays unperturbed
mitotic progression. The indicated cell lines were
infected with histone H2B-GFP-expressing retro-
viruses and analyzed with time-lapse fluorescence
microscopy. Mitotic length of individual cells (from
DNA condensation to anaphase onset) was deter-
mined and summarized in the box-and-whisker
plot (n = 50). Deletion of p31comet significantly
extended the duration of mitosis and could be
rescued with FLAG-p31comet (***p < 0.001).(p31KO) cells were generated from HeLa (Figure S1B). Genomic
DNA sequencing validated that deletions occurred at the
TALEN-targeting region of MAD2L1BP, resulting in premature
termination of the gene products (Figure S1A). Knockout of
p31comet did not alter the expression of MCC components,
including MAD2, BUBR1, BUB3, and CDC20 (Figures 1A and
S1A). As anticipated, no MAD2 or CDC20 was found in p31cometCell Reports 14, 1086–1099,immunoprecipitates from p31KO (Fig-
ure 1B). The p31comet gene could also be
ablated in HCT116 cells (Figure 1A), illus-
trating that the non-essential nature of
p31comet was not limited to one cell type.
The absence of p31comet nevertheless
led to abnormal mitosis. Time-lapse
microscopy revealed that mitosis was
significantly longer in p31KO than in the
parental HeLa (Figure 1D) or HCT116 cells
(Figure S1C). To verify the causal rela-
tionship with p31comet, recombinant
FLAG-p31comet was reintroduced into
the p31KO cells to a level comparable to
the endogenous p31comet before gene
disruption (Figure 1C). The extension of
mitosis caused by p31comet knockout
was completely reversed by the recombi-
nant p31comet (Figure 1D).Taken together, these results indicate that although knockout
of p31comet delays mitotic exit, p31comet is not essential for cells
to complete mitosis.
Mitotic Exit Is Delayed in the Absence of p31comet
We next analyzed whether p31comet is important for prolonged
mitotic arrest. Spindle poisons, including nocodazole (NOC),February 9, 2016 ª2016 The Authors 1087
activate the SAC and block cells in a prometaphase-like state.
After washing out the NOC, the cells recovered rapidly from
the checkpoint and undergo anaphase (Figure 2A, top). In
contrast, mitotic exit was delayed by more than twofold in
p31KO cells, which could be reversed by reintroducing FLAG-
p31comet. Similar results were obtained using p31comet-deficient
HCT116 cells (Figure S1D). The delay of mitotic exit in p31KO
cells increased dramatically upon longer incubation in NOC
(Figure 2A, middle), illustrating the importance of p31comet for
recovery after prolonged activation of the SAC.
The results from single-cell analysis were corroborated by
other approaches, including the delays of the decrease of
mitotic markers (histone H3Ser10 phosphorylation, cyclin B1,
and CDC20) (Figure 2B) and cytokinesis (Figure 2C) after release
from mitotic block. Mitotic exit eventually occurred after a delay
of 60 min (Figures 2D and 2E), again indicating that p31comet is
not absolutely required for checkpoint inactivation. Finally, timely
mitotic exit was restored when p31comet was reintroduced (Fig-
ures 2D and 2E).
Given that p31KO cells required a longer time to recover from
the SAC than p31comet-containing cells, we predicted that
p31KO cells should be hypersensitive to spindle-disrupting
agents. Indeed, a lower concentration of NOCwas able to induce
a mitotic delay in p31KO than in parental HCT116 (Figure S1E).
The delay in mitotic exit in p31KO was likely to be due to the
time required for turning off the SAC. To test this hypothesis,
cells were first released from NOC-mediated block into medium
containing the proteasome inhibitor MG132—this trapped the
cells in metaphase and satisfied the SAC—before finally
released into drug-free medium. Using this method, anaphase
onset was no longer delayed in p31KO (Figure 2A, bottom).
An MPS1 inhibitor (MPS1i) was also used to abolish SAC
activation. In normal cells, this triggered a rapid mitotic exit as
indicated by cells containing G1 DNA content (Figure S2A) and
a decrease of mitotic markers (Figure S2B). In contrast, p31KO
cells entered G1 only after a long delay following MPS1i treat-
ment, again illustrating that p31comet disruption affected SAC
inactivation.
Collectively, these data demonstrate that after a delay,
SAC inactivation and mitotic exit can occur in the absence of
p31comet.
p31comet Is Partially Responsible for MAD2 Inactivation
Given that SAC inactivation involves C-MAD2 to O-MAD2 con-
version, we next analyzed the conformation of MAD2 in the
absence of p31comet. A spin column-based ion exchange chro-
matography was adopted. O-MAD2 and C-MAD2 were eluted
with relatively low and high salt concentrations, respectively (Fig-
ure 3A). Similar to endogenous MAD2, recombinant MAD2 was
predominantly in the O-MAD2 conformation (Luo et al., 2004).
AMAD2L13Qmutant that only exists in the C-MAD2 conformation
(Mapelli et al., 2007) eluted at relatively high salt concentration,
verifying that the ion exchange chromatography was able to
resolve the two forms of MAD2.
Consistent with previous studies (Luo et al., 2004), endoge-
nous MAD2 was present predominantly as O-MAD2 (Figure 3B).
We found that p31KO contained more C-MAD2 than in control
cells. As the total amount of MAD2 remain unchanged (Fig-1088 Cell Reports 14, 1086–1099, February 9, 2016 ª2016 The Authoure 3C), there was a net shift from O-MAD2 to C-MAD2 in the
absence of p31comet. Introduction of FLAG-p31comet reversed
this shift in MAD2 equilibrium. It is notable that C-MAD2 to
O-MAD2 conversion was only partially impaired in p31KO
(compare with cells that were completely defective in this con-
version below). An involvement of p31comet in MAD2 inactivation
was confirmed using an in vitro C-MAD2 to O-MAD2 conversion
assay (see later).
Conceptually, a delay in SAC inactivation could be caused by
a stimulation of MAD2 activation and/or a suppression of MAD2
inactivation. To see whether MAD2 activation is affected by
p31comet, the level of MCC was analyzed after the SAC was acti-
vated with NOC. The level of MAD2-CDC20 complexes
increased after p31comet was disrupted and could be reversed
by FLAG-p31comet (Figure 3C). Similarly, binding of MAD2 with
other MCC components (BUBR1 and BUB3) increased in
p31KO cells (Figure S2C). Binding of APC4 (an APC/C subunit)
to MCC also increased (p31comet itself did not interact with
APC4), indicating an enhancement of functional inhibition of
APC/C after p31comet was disrupted (Figure S2C).
Taken with the data below, these results demonstrate that
p31comet is involved in both suppressing MAD2 activation and
inducing MAD2 inactivation.
TRIP13 Is Essential for Converting MAD2 to the Open
Conformation
Given that p31comet is not absolutely required for SAC inactiva-
tion, we next addressed whether TRIP13, a recently identified
partner of p31comet, is essential for mitosis. We found that
HeLa and HCT116 cells remained viable after the TRIP13 gene
was disrupted using CRISPR-Cas9 (Figure S3A). Interestingly,
the expression of p31comet was elevated in TRIP13KO cells (Fig-
ure 4A; this is addressed later here).
In contrast to WT and p31KO cells, TRIP13KO contained MAD2
entirely in the C-MAD2 conformation (Figure 4B), suggesting that
TRIP13 is required for converting C-MAD2 to O-MAD2 in the cell.
Expression of a FLAG-TRIP13 construct restored the level of
p31comet (Figure 4C) as well as the C-MAD2 to O-MAD2 equilib-
rium (Figure 4D).
To further validate the essential role of TRIP13 in C-MAD2 to
O-MAD2 conversion, we developed an in vitro MAD2 conversion
assay. Lysates of TRIP13KO cells were supplemented with an
ATP-regeneration system and incubated for 90 min (Figure 4E).
During this time, the MAD2 in the TRIP13KO lysates remained
in the C-MAD2 conformation. Mixing in a small portion of HeLa
cell lysates (10:1 ratio) was sufficient to convert the C-MAD2 in
the TRIP13KO lysates into O-MAD2. Moreover, addition of bacte-
rially expressed GST-TRIP13 was also sufficient to convert the
C-MAD2 into O-MAD2 in vitro (Figure 4F).
Consistent with the high levels of p31comet and C-MAD2 in
TRIP13KO, there was a corresponding increase in p31comet-
MAD2 complexes (despite the fact that the expression of total
MAD2 was reduced) (Figure 4G). Dissociation of these
p31comet-MAD2 complexes was promoted by mixing of
TRIP13-containing lysates (Figure 4H).
Given that MAD1 was eluted at similar fractions as C-MAD2 in
ion exchange chromatography (Figure S3B), it is possible that
the shift of MAD2 to high-salt fractions in TRIP13KO was simplyrs
Figure 2. p31comet Is Important for Mitotic Exit after Prolonged SAC Activation
(A) Mitotic exit is delayed in p31comet-deficient cells. Histone H2B-GPF-expressing HeLa, p31KO, and p31KO expressing FLAG-p31comet (F-p31) were syn-
chronized in mitosis with NOC (2 hr) followed with mechanical shake-off. (Top) The cells were washed twice with PBS and released into drug-free medium. The
cells were imaged immediately with time-lapse microscopy, and mitotic progression was analyzed. (Middle) The mitotic cells were further incubated in
NOC-containing medium for another 4 hr before releasing and imaging. (Bottom) Cells were prepared as in the top, except that they were first released into
MG132-containing medium (2 hr) before released into drug-free medium for imaging.
(B) Mitotic exit is delayed in p31comet-deficient cells. HeLa and p31KOwere synchronized inmitosis with NOC. The cells were then released into NOC-freemedium
and harvested at the indicated time points. Lysates were prepared, and the expression of the indicated proteins was analyzed with immunoblotting. Mitotic exit
was indicated by the decrease of histone H3Ser10 phosphorylation, cyclin B1, and CDC20.
(legend continued on next page)
Cell Reports 14, 1086–1099, February 9, 2016 ª2016 The Authors 1089
Figure 3. p31comet Facilitates the Mainte-
nance of MAD2 in the Open Conformation
(A) MAD2 is mainly present in the O-MAD2
conformation in the cell. Control HeLa or cells
transfected with plasmids expressing HA-tagged
MAD2 or a C-MAD2-specific mutant (MAD2(LQ))
were analyzed using spin column-based ion
exchange chromatography. Fractions were eluted
with different concentrations of buffer B (%B,
Experimental Procedures) and analyzed with
immunoblotting for MAD2. The fractions corre-
sponding to O-MAD2 and C-MAD2 are indicated
at the top. The positions of the endogenous and
recombinant MAD2 are indicated.
(B) C-MAD2 to O-MAD2 conversion is partially
impaired in the absence of p31comet. MAD2
conformation in HeLa cells, p31KO, and p31KO ex-
pressing FLAG-p31comet was analyzed with ion
exchange chromatography.
(C) Knockout of p31comet induces an accumulation
of MCC. The indicated cell lines were enriched
in mitosis with NOC. Lysates were prepared and
subjected to immunoprecipitation using anti-
serum against p31comet, MAD2, or CDCD20. The
immunoprecipitates and total lysates were then
analyzed using immunoblotting.due to an increase in MAD2-MAD1 complexes. In disagreement
with this, MAD2-MAD1 complexes were present at similar levels
in HeLa and TRIP13KO cells (Figure S3C). Removal of MAD1
from TRIP13KO lysates by immunodepletion only slightly reduces
the total MAD2 (Figure S3D). Furthermore, MAD2 was still eluted
at high-salt fractions after MAD1 was depleted (Figure S3E).
Collectively, our data indicate that TRIP13 is required for con-
verting C-MAD2 into O-MAD2.
Loss of TRIP13 Disrupts the SAC
Given that TRIP13 is required for C-MAD2 into O-MAD2 conver-
sion, we predicted that TRIP13-deficient cells are unable to inac-
tivate the SAC to inducemitotic exit. Accumulation and decrease
of mitotic histone H3Ser10 phosphorylation occurred relatively
normally in synchronized TRIP13KO (Figure 5A), indicating that
unperturbed mitosis was unaffected by the absence of TRIP13.
Live-cell imaging further detailed that TRIP13KO could undergo
mitosis relatively normally (albeit shorter than in normal cells,
see Figure 6B).
In complete opposite to our expectation, TRIP13KO cells were
unable to be trapped in mitosis with NOC (Figure 5B). Compared(C) Delayed entry into G1 in the absence of p31
comet. HeLa and HCT116 (both WT and p31KO) were blocked i
were fixed at the indicated time points and analyzed with flow cytometry. The positions of 2N (G1) and 4N (
(D) Delayed disappearance of mitotic markers in p31comet-deficient cells. HeLa, p31KO, and p31KO expressin
NOC. The cells were then released into NOC-free medium and harvested at the indicated time points. Lysate
(E) Entry into G1 frommitotic arrest is delayed without p31
comet. Different cells were released frommitotic bloc
points and analyzed with flow cytometry.
1090 Cell Reports 14, 1086–1099, February 9, 2016 ª2016 The Authorswith control cells, histone H3Ser10 phos-
phorylation increased only transiently,
suggesting that the SAC either could not
be activated properly or be maintained inthe absence of TRIP13. Similar results were obtained from
multiple clones of TRIP13KO cells in both HeLa (Figure S4A)
and HCT116 background (Figure S4B).
Time-lapse microscopy was further used to verify that TRIP13
is required for maintaining the SAC at the single-cell level. While
control NOC-treated HeLa cells remained in mitosis for 10 hr
before undergoing slippage, TRIP13KO cells underwent slippage
in less than 1 hr (Figure 5C). The SAC could be restored with re-
combinant TRIP13, supporting a causal relationship between
TRIP13 inactivation and the loss of the checkpoint. As a control,
expression of TRIP13 alone did not affect the duration of mitotic
arrest in HeLa cells.
TRIP13-rescue experiments were also performed to analyze
histone H3Ser10 phosphorylation. While exposing HeLa cells
to NOC induced an accumulation of histone H3Ser10 phosphory-
lation, no phosphorylation was detected using TRIP13KO
(Figure 5D). Histone H3Ser10 phosphorylation was also analyzed
in individual cells using flow cytometry (Figure 5E). In both
assays, the deficiency in NOC-induced histone H3Ser10 phos-
phorylation could be rescued with recombinant TRIP13. The
SAC was not restored with a TRIP13 Walker-A domain mutant,n mitosis with NOC and released as in (B). The cells
G2/M) DNA contents are indicated.
g FLAG-p31comet were synchronized in mitosis with
s were prepared and analyzed with immunoblotting.
k as in (D). The cells were fixed at the indicated time
Figure 4. TRIP13 Is Essential for Converting MAD2 to the Open Conformation
(A) Disruption of TRIP13 in HeLa and HCT116 cells. TRIP13 gene was disrupted in both HeLa and HCT116 cells using CRISPR-Cas9 (TRIP13KO, TRIP13
knockout). Lysates were prepared, and the expression of TRIP13 and other proteins was analyzed with immunoblotting (note that 10 mg was loaded for HeLa and
20 mg was loaded for HCT116).
(B) C-MAD2 to O-MAD2 conversion requires TRIP13. MAD2 conformation in parental HeLa or HCT116 and the corresponding TRIP13KO cells was analyzed using
ion exchange chromatography.
(C) An increase in p31comet after TRIP13 disruption can be reversed by recombinant TRIP13. Lysates of HeLa, TRIP13KO, or TRIP13KO infected with retroviruses
producing FLAG-TRIP13 were analyzed with immunoblotting.
(D) Recombinant TRIP13 restores C-MAD2 to O-MAD2 conversion in TRIP13KO. MAD2 conformation in parental HeLa, TRIP13KO, or TRIP13KO infected with
retroviruses producing FLAG-TRIP13 was analyzed with ion exchange chromatography.
(E) TRIP13-dependent C-MAD2 to O-MAD2 conversion in cell lysates. Lysates of HeLa or TRIP13KO were supplemented with an ATP-regeneration system and
incubated at 25C. A third reaction included mixing of TRIP13KO and HeLa lysates at a 10:1 ratio. At the indicated time points, the reactions were stopped, and
MAD2 conformation was analyzed.
(legend continued on next page)
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which abolishes the ATPase activity (Hanson and Whiteheart,
2005), indicating that SAC functions requires the presence of
catalytic-active TRIP13 (Figure 5F).
MAD2 was enriched at the kinetochores of both HeLa and
TRIP13KO mitotic cells (Figure S4C). This indicated that the
lack of SAC was not due to aberrant MAD2 recruitment and sug-
gested that downstream activation of MCCmay be dysregulated
in TRIP13KO. Since TRIP13KO could not be trapped in mitosis
by conventional methods, we first synchronized the cells to G2
using a CDK1 inhibitor before releasing them into NOC. A protea-
some inhibitor (MG132) was added to prevent the TRIP13KO cells
from escaping mitosis. Figure 5G shows that TRIP13KO con-
tained less MCC than control cells, again supporting the idea
that TRIP13 is required for the SAC activation.
As the expression of total MAD2 decreased in TRIP13KO cells
(Figure 4C), we also examined the effects of MAD2 expression
on the SAC. While the SAC in TRIP13KO cells could be restored
by TRIP13, it remained defective after ectopic expression of
MAD2 (Figure S4D), indicating that the defective SAC in
TRIP13KO cells was not caused by a decrease in MAD2.
Hence, paradoxically, instead of delayed SAC inactivation,
disruption of TRIP13 resulted in defective activation of the
SAC. Although exclusively C-MAD2 was present in these cells,
it was unable to be incorporated into MCC to establish the
checkpoint.
p31comet Promotes TRIP13-Dependent C-MAD2 to
O-MAD2 Inactivation
One trivial explanation of the lack of SAC in TRIP13KO is the
increase of p31comet in these cells (Figures 4A and 5D). To test
this possibility, we first depleted p31comet with siRNA and
demonstrated that TRIP13KO cells were still without SAC (Fig-
ure S4E). We further generated cells lacking both TRIP13 and
p31comet together (Figure 6A). During unperturbed cell cycle,
TRIP13KO cells already displayed a relatively short mitosis (Fig-
ure 6B). This was not caused by changes in p31comet because
the mitotic length was not restored in the double-knockout
cells. Similar to cells lacking TRIP13 alone, cells lacking both
TRIP13 and p31comet together were defective in SAC activation,
as revealed by histone H3Ser10 phosphorylation (Figure 6C) and
mitotic length analysis (Figure 6D). Furthermore, similar to
TRIP13KO (Figure 4B), the double-knockout cells contained
mainly C-MAD2 (Figure 6E).
Collectively, these data indicated that the defects in SAC acti-
vation and MAD2 conversion in TRIP13KO were independent on
p31comet. In fact, expressing FLAG-TRIP13 in TRIP13KO/p31KO
double-knockout cells was sufficient to reestablish the C- to
O-MAD2 equilibrium (Figures 6A and 6E). Nevertheless, p31comet(F) Bacterially expressed TRIP13 stimulates C-MAD2 to O-MAD2 conversion in
system and incubated in either the presence or absence of bacterially expressedG
was analyzed.
(G) Increased level of p31comet-MAD2 complexes in TRIP13KO. Lysates of HeLa,
against p31comet. The expression of the indicated proteins in total lysates and p3
(H) TRIP13 stimulates the dissociation of p31comet-MAD2 complexes. Lysates of H
supplemented with an ATP-regeneration system and incubated at 25C. The c
subjected to immunoprecipitation using antiserum against p31comet. The express
was analyzed with immunoblotting.
1092 Cell Reports 14, 1086–1099, February 9, 2016 ª2016 The Authowas involved in facilitating TRIP13-dependent MAD2 conver-
sion. Addition of purified GST-TRIP13 to TRIP13-deficient
lysates effectively converted C-MAD2 to O-MAD2 (Figure 6F).
In contrast, MAD2 conversion was significantly slower in
lysates that also lacked p31comet. These data indicated that
p31comet increases the efficiency of TRIP13-dependent MAD2
inactivation.
Taken together, these data reveal that although p31comet
accumulates in TRIP13KO, it is not responsible for the defective
SAC activation in these cells. TRIP13 is required for the conver-
sion of C-MAD2 to O-MAD2, a process that is promoted by
p31comet.
Interaction of p31comet with Either MAD2 or TRIP13 Can
Promote Mitotic Exit
Recent in vitro studies indicated that p31comet acts both as an
adaptor between MAD2 and TRIP13 as well as an activator of
TRIP13 (Ye et al., 2015). As our data showed that MAD2 could
still be inactivated in the absence of p31comet, we next examined
the interaction between MAD2, TRIP13, and p31comet in the cell.
Co-immunoprecipitation analysis indicated that both MAD2 and
p31comet could interact with TRIP13 (Figure 7A). Significantly,
MAD2 also co-immunoprecipitated with TRIP13 in a p31comet-
deficient background, suggesting the possibility of a direct
TRIP13-MAD2 interaction (Figure 7B).
To understand how p31comet promoted TRIP13-dependent
MAD2 inactivation, we generated a Q83A/F191A mutant of
p31comet (p31(QF) herein) that cannot bind MAD2 (Yang et al.,
2007). Figure S5A confirms that p31(QF) did not interact with
MAD2. To test whether interaction with TRIP13 is important for
p31comet’s function, we further generated a mutant of p31comet
that disrupted binding to TRIP13 (P228A/K229A, Ye et al.,
2015, p31(PK) herein). Figure S5B shows that while p31comet
bound robustly to an ATPase-inactive mutant of TRIP13 (which
forms stable hexamers, Ye et al., 2015, and trapped p31comet
better than WT TRIP13 in our assays), this interaction was abol-
ished in p31(PK).
As shown above, TRIP13KO cell lysates contained predomi-
nantly C-MAD2, which could be converted into O-MAD2 with
GST-TRIP13 in a p31comet-dependent manner (Figure 7C). In
contrast, the non-MAD2 binding p31(QF) did not promote
MAD2 conversion. The non-TRIP13 binding p31(PK) was also
impaired in inducing MAD2 conversion in vitro (but was margin-
ally more efficient than p31(QF)). In agreement with these results,
the accumulation of MCC in p31KO could be rescued with
p31comet, p31(PK), but not p31(QF) (Figure 7D). Figure 7E indi-
cates that all the p31comet constructs were expressed at levels
comparable to endogenous p31comet.lysates. Lysates of TRIP13KO were supplemented with an ATP-regeneration
ST-TRIP13. After 45min, the reactions were stopped, andMAD2 conformation
p31KO, and TRIP13KO were subjected to immunoprecipitation using antiserum
1comet-immunoprecipitates was analyzed with immunoblotting.
eLa, TRIP13KO, or a mixture of TRIP13KO lysates with HeLa lysates (10:1) were
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Figure 5. TRIP13 Is Essential for the Activation of the SAC
(A) TRIP13 is not required for unperturbed mitosis. HeLa and TRIP13KO were synchronized at early S phase with a double thymidine procedure and released into
the cell cycle. The cells were harvested at the indicated time points and analyzed with immunoblotting.
(B) TRIP13-deficient cells are unable to maintain a mitotic arrest. HeLa and TRIP13KO were synchronized at early S phase with a double thymidine procedure and
released into the cell cycle in the presence of NOC. The cells were harvested at the indicated time points and analyzed with immunoblotting.
(C) TRIP13 is required for prolonged mitotic arrest. HeLa and TRIP13KO were infected with FLAG-TRIP13-expressing retroviruses. Lysates were produced and
analyzed with immunoblotting (upper). The cells were also incubated with NOC and analyzed with time-lapse fluorescence microscopy. The mitotic length of
(legend continued on next page)
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Although both p31(QF) and p31(PK) have relatively weak
MAD2-inactivating activity in vitro, cells expressing them were
able to enter G1 with the same kinetics as cells expressing WT
p31comet (Figure 7E). In contrast, p31comet that could bind neither
MAD2 nor TRIP13 (p31(QF/PK)) (Figures S5A and S5C) were
unable to rescue the mitotic exit delay caused by p31comet
knockout (Figure 7F). Not surprisingly, p31(QF/PK) was also
unable to promote C-MAD2 to O-MAD2 conversion in vitro
(Figure 7C) or MCC inactivation (Figure 7G). Finally, compared
with cells expressing p31(QF) or p31(PK), p31(QF/PK)-express-
ing cells displayed an impaired MAD2 equilibrium similar to cells
without any p31comet (Figure 7H).
Taken together, these results indicated that although direct
binding of p31comet to both MAD2 and TRIP13 is important for
facilitating TRIP13-dependent MAD2 inactivation in vitro,
p31comet mutants that lack either one of these functions appear
to be sufficient to promote mitotic exit.
DISCUSSION
Existing evidence predicts that p31comet and TRIP13 are essen-
tial for mitosis. However, our results indicate that both proteins
are not essential proteins for the unperturbed cell cycle. The
conclusion was based on evidence from gene disruption in
two different cell lines. Given that both inactivation and activa-
tion of SAC were affected in p31KO and TRIP13KO, respectively,
deficiencies of the SAC appear to be well tolerated during un-
perturbed mitosis. It should be noted that mitosis was actually
delayed in p31comet-deficient cells (Figures 1D and S1C) and
shortened in TRIP13-deficient cells (Figure 6D). However, these
defects did not appear to compromise cell survival in both
HeLa and the more chromosomally stable HCT116. An implica-
tion is that an effective SAC is not absolutely necessary for cell
survival, at least in the cell lines examined. As the use of the
same gene-editing tools is challenging in cells with finite prolif-
eration potential, it is currently unclear whether the same is also
true for normal cells. In this connection, Trip13-deficient mice
(generated with gene-trap techniques and contained vastly
reduced level of Trip13) are born at approximately two-thirds
the expected ratio but are otherwise grossly normal (Li and
Schimenti, 2007).
The delay in mitotic exit in the absence of p31comet (Figure 2)
correlated with an increase in MCC (Figures 3C and S2C),
suggesting that p31comet might antagonize MAD2 activation.
Disruption of p31comet also prevented TRIP13-dependentindividual cells was determined (from DNA condensation to slippage or cell dea
rescued with TRIP13 (***p < 0.001).
(D) Recombinant TRIP13 reestablishes the SAC in TRIP13-deficient cells. HeLa
cells were then incubated with either buffer or NOC for 16 hr before analyzed wi
(E) Recombinant TRIP13 restores histone H3Ser10 phosphorylation in TRIP13-defic
plasmids. EGFP-expressing plasmids were co-transfected as markers. The ce
H3Ser10- and EGFP-positive cells was analyzed with bivariate flow cytometry.
(F) ATP hydrolase activity of TRIP13 is required for restoring the SAC in TRIP13-d
TRIP13 or TRIP13(WA) mutant. The cells were then incubated with either buffer o
(G) Defective MCC formation in the absence of TRIP13. HeLa, p31KO, TRIP13KO, o
the cells were incubatedwith the CDK1 inhibitor RO3306 for 5 hr to trap cells in G2
MG132 for 2 hr to enrich cells in mitosis (as indicated by histone H3Ser10 phosphor
antibody against MAD2. Both the total lysates and the immunoprecipitates were
1094 Cell Reports 14, 1086–1099, February 9, 2016 ª2016 The AuthoMAD2 inactivation in vitro (Figure 6F), indicating a role of
p31comet in MAD2 inactivation. This notion is also supported by
the shift of C-MAD2 and O-MAD2 equilibrium in p31KO (Fig-
ure 3B). Hence, a combination of a higher level of MCC attained
during SAC activation and a slower rate of MAD2 inactivation
after the SAC was satisfied contributed to the delay in mitotic
exit in p31KO.
One of the surprising findings from this study is thatmitotic exit
could occur in p31KO, albeit at a slower rate than p31comet-con-
taining cells (Figure 2). Likewise, in vitro MAD2 inactivation could
occur in a p31comet-deficient background (Figure 6F). These re-
sults are consistent with the model that TRIP13-dependent
MAD2 inactivation can occur in the absence of p31comet. Given
that TRIP13 could associate with MAD2 without p31comet (Fig-
ure 7B), it is possible that MAD2 inactivation could occur at a
relatively slow rate without p31comet. These results deviate
from previous yeast three-hybrid and in vitro studies, in which
the interaction between TRIP13 and MAD2 is dependent on
the presence of p31comet (Ye et al., 2015). Ye et al. (2015) pro-
posed a two-states binding model in which MAD2 first binds
TRIP13 through a transient TRIP13-p31comet interaction followed
by a direct interaction between TRIP13 and MAD2. Our results
suggested that TRIP13-p31comet-MAD2 might not be absolutely
required for TRIP13 to act on MAD2.
We found that mitotic exit could be promoted by p31(QF), a
mutant that cannot bind MAD2 (Figure 7E). Hence, it is possible
that although p31(QF)-expressing cells contained elevated
levels of MCC (Figure 7D), the stimulation of TRIP13 activity by
p31comet was sufficient to promote mitotic exit. However, the
non-TRIP13 binding p31(PK) also facilitated mitotic exit (Fig-
ure 7E). It is possible that p31(PK) was able to make MAD2 a
better substrate for TRIP13. In agreement with this, both
p31(QF) and p31(PK) were able to stimulate TRIP13-dependent
MAD2 inactivation (Figure 7H). In contrast, p31comet that bound
neither MAD2 nor TRIP13 was unable to promote mitotic exit
(Figure 7F) or MAD2 inactivation (Figure 7H). It is important to
note that we cannot exclude the possibility that p31(PK) or
p31(QF) could still interact weakly or transiently with TRIP13 or
MAD2, respectively. However, our available data indicate that
even with a Walker B mutant of TRIP13 (which probably acts
as a substrate trap for p31comet-MAD2), no p31(PK) was de-
tected to form a complex (Figure S5B).
Although TRIP13 is responsible for inactivating the SAC,
TRIP13KO cells were unable to activate the SAC (Figures 5B–
5E). In agreement with this, a C. elegans TRIP13 (PCH-2) mutantth) (n = 50) (lower). Deletion of TRIP13 abolished mitotic arrest and could be
and TRIP13KO were transfected with FLAG-TRIP13-expressing plasmids. The
th immunoblotting.
ient cells. HeLa and TRIP13KOwere transfectedwith FLAG-TRIP13-expressing
lls were then incubated with NOC for 6 hr. The portion of phosphor-histone
eficient cells. HeLa and TRIP13KO were transfected with plasmids expressing
r NOC for 16 hr before analyzed with immunoblotting.
r double-knockout cells were released from double thymidine block. After 7 hr,
. After washing out the RO3306 (30min), the cells were incubated with NOC and
ylation). Lysates were prepared and subjected to immunoprecipitation using an
analyzed with immunoblotting.
rs
Figure 6. Inactivation of p31comet Is Not Sufficient to Restore the SAC in TRIP13 Knockout Cells
(A) Ablation of both TRIP13 and p31comet. Lysates from cells lacking TRIP13 and p31comet, either individually or together, were analyzed with immunoblotting.
Lysates from TRIP13KO/p31KO expressing FLAG-TRIP13 was also loaded. Equal loading of lysates was confirmed by immunoblotting for actin (the upper bands
were signals from the TRIP13 blot).
(B) The shortening of unperturbed mitosis in TRIP13KO cannot be rescued with co-knockout of p31comet. The indicated cell lines were infected with histone H2B-
GFP-expressing retroviruses and analyzed with time-lapse microscopy. The mitotic length of individual cells was determined (n = 50). Mitosis was significantly
shortened after deletion of TRIP13 or both TRIP13 and p31comet together (***p < 0.001).
(C) Removal of p31comet cannot restore the SAC in TRIP13KO. The indicated cell lines (including two different clones of TRIP13KO/p31KO) were incubated with
either buffer or NOC for 16 hr before analyzed with immunoblotting.
(D) Removal of p31comet cannot restore the SAC in TRIP13KO. The indicated cell lines were infected with histone H2B-GFP-expressing retroviruses, incubated
with NOC, and analyzed with time-lapse microscopy. Themitotic length of individual cells was determined (n = 50). Mitotic arrest was significantly shortened after
deletion of TRIP13 or TRIP13 and p31comet together (***p < 0.001).
(E) Defective C-MAD2 to O-MAD2 conversion in TRIP13KO cannot be rescued by removing p31comet. MAD2 conformation in p31KO, TRIP13KO/p31KO, or
TRIP13KO/p31KO infected with retroviruses producing FLAG-TRIP13 was analyzed with ion exchange chromatography.
(F) Efficient TRIP13-dependent C-MAD2 to O-MAD2 conversion requires p31comet. Lysates of TRIP13KO or TRIP13KO/p31KO were supplemented with an ATP-
regeneration system and incubated in either the presence or absence of bacterially expressed GST-TRIP13. At the indicated time points, the reactions were
stopped, and MAD2 conformation was analyzed with ion exchange chromatography.
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was also found to be defective in SAC activation (Nelson et al.,
2015). This unexpected result may be reconciled by the fact
that MAD2 equilibrium was disrupted (Figure 4B). Although
TRIP13-deficient cells contained exclusively C-MAD2, the
C-MAD2 was unable to be incorporated into MCC (Figure 5G).
The normal localization ofMAD2 to the kinetochores (Figure S4C)
and MAD2-MAD1 complex formation (Figure S3C) suggested
that perhaps the propagation of the MAD2 signal to the MCC
was affected without TRIP13. One possibility is that the activa-
tion of the SAC may require dynamic conversion of C-MAD2
fromO-MAD2, rather than simply the presence of C-MAD2 itself.
These are provocative ideas that will need to be tested in the
future, for example, by replacing the endogenous MAD2 with a
C-MAD2-specific mutant.
The fact that TRIP13KO cells were unable to be enriched in
mitosis presented a difficulty for studying the role of TRIP13 in
SAC inactivation. Nevertheless, by using an in vitro MAD2
conversion assay, we demonstrated that TRIP13 could induce
C-MAD2 to O-MAD2 conversion, particularly in a p31comet-con-
taining environment (Figure 6F). In another approach using G2
synchronization and a proteasome inhibitor, we demonstrated
that MCC formation was defective without TRIP13 (Figure 5G).
These data are consistent with previous RNAi experiments
showing that depletion of TRIP13 results in a delay in mitotic
exit in MCF7 cells (Wang et al., 2014). However, our results are
inconsistent with these previous experiments in one important
aspect. While Wang et al. (2014) showed that knockdown of
TRIP13 inhibits cell proliferation in breast cancer cell lines, our
gene-disruption studies showed that both HeLa and HCT116
cells could survive without TRIP13. A more elegant demon-
stration of a role of TRIP13 in SAC inactivation will involve
approaches that allow us to inactivate TRIP13 rapidly during a
mitotic block.
Loss of TRIP13 was associated with an accumulation of
p31comet and a decrease in MAD2. They were unlikely to be
off-target effects because they could be reversed with a recom-
binant TRIP13 (Figure 4C). Although these changes in p31comet
and MAD2 were not responsible for the SAC defects in
TRIP13-deficient cells (Figures 6C, 6D, and S4D), it is neverthe-
less an interesting phenomenon that may be inextricably linked
to the SAC. One possible explanation is that the accumulation
of C-MAD2 caused by TRIP13-knockout could stabilize
p31comet.
As the expression of TRIP13 affects SAC activation, a predic-
tion from this study is that TRIP13 should be tightly regulated to
prevent genome instability. TRIP13 gene is amplified or its
product is overexpressed in several cancers (Rhodes et al.,
2004; Banerjee et al., 2014; Larkin et al., 2012; van Kester
et al., 2012). TRIP13 is also one of the top genes associated
with chromosomal instability in human cancers (Carter et al.,
2006). A reasonable surmise is that similar to p31comet (Chan
et al., 2008b), overexpression of TRIP13 may induce premature
mitotic exit. In contrast, downregulation of TRIP13 may induce
genome instability through delayed mitotic exit. The resulting in-
crease in C-MAD2 may also compromise SAC activation during
mitosis. Yet another speculation is that similar to our previous
findings for p31comet (Ma et al., 2012), the level of TRIP13 may
affect the sensitivity of antimitotic drug treatments.1096 Cell Reports 14, 1086–1099, February 9, 2016 ª2016 The AuthoEXPERIMENTAL PROCEDURES
DNA Constructs
See Supplemental Experimental Procedures for constructs and details of
subcloning.
Cell Culture
See Supplemental Experimental Procedures for details of cells used in this
study, flow cytometry, and cell imaging.
Cell Cycle Synchronization
Cell cycle synchronization was performed as described (Ma and Poon, 2011a).
Briefly, mitotic cells were obtained by incubating cells released from a double
thymidine method with NOC before the mitotic cells were isolated with
mechanical shake-off. In some cases, mitotic cells were washed twice with
PBS and released into drug-free medium. Mitotic TRIP13-deficient cells
were obtained by first synchronizing cells to G2 using a double thymidine
method followed by 4 hr of RO3306 treatment. The RO3306-treated cells
were then released to drug-free medium for 30 min and before addition of
MG132 for 1 hr. The cells were then further treated with NOC for 30 min to
activate the SAC.
Antibodies and Immunological Methods
Monoclonal antibodies against b-actin, FLAG (Sigma-Aldrich), HA, CDC20,
MAD1 (Santa Cruz Biotechnology), MAD2, BUB3, and CDC27 (BD Transduc-
tion Laboratories) were obtained from the indicated suppliers. Polyclonal
antibodies against APC4 (Abcam), BUBR1, HA (Bethyl Laboratories), FLAG
(Rockland Immunochemicals), phosphor-histone H3Ser10, and TRIP13 (Santa
Cruz Biotechnology) were obtained from the indicated suppliers. Antibodies
against cyclin B1 were gifts from Julian Gannon (Cancer Research). Polyclonal
antibodies against MAD2 (Ma and Poon, 2011b) and p31comet (Ma et al.,
2012) were prepared as previously described. Autoantibody against human
nuclear ANA-centromere CREST was obtained from Fitzgerald Industries.
Anti-FLAG (M2)-conjugated agarose for immunoprecipitation was obtained
from Sigma-Aldrich. Immunoblotting was performed as previously described
(Poon et al., 1995), except that a ChemiDoc Touch imaging system (Bio-
Rad) was used to detect the signals. Immunoprecipitation and immunostaining
of MAD2 were performed as described (Ma and Poon, 2011b).
MAD2 Conformation Analysis and Cell Lysate MAD2 Conversion
Assays
MAD2 conformation was determined using spin column-based ion exchange
chromatography. Spin columns with 100 ml of SOURCE 15Q matrix (GE
Healthcare) were washed sequentially with 1 M NaCl, 1 M HCl, 500 mM
NaOH and equilibrated with buffer A (5 mM Tris-HCl [pH 7.5], 25 mM
NaCl, 0.5 mM EDTA, 5 mM NaF, 0.01% NP40). Cell lysates (400 mg) were
diluted ten times with water before being loaded onto the column (100 ml).
The lysate loaded columns were washed three times with buffer A and
then step eluted with 150 ml buffer A containing 5%–22.5% of buffer B
(5 mM Tris-HCl [pH 7.5], 1.025 M NaCl, 0.5 mM EDTA, 5 mM NaF, 0.01%
NP40). The eluted fractions were mixed with SDS-sample buffer and
analyzed using immunoblotting.
For MAD2 conversion assay, cell lysates (400 mg) were diluted 2-fold with
water and supplemented with 1 mM ATP, 20 mM MgCl2, 0.1 mg/ml creatine
kinase, and 10 mM phosphocreatine. The lysates were incubated with purified
GST-TRIP13 (1 mg) or cell lysates (40 mg) at 25C for the indicated time. The
reaction were stopped by 5-fold dilution with water and loaded onto the spin
column to analyze the MAD2 conformation. GST-TRIP13 was expressed
in bacteria and purified with GSH-agarose chromatography as described
(Poon et al., 1995), except that 18C was used for induction.
Statistical Analysis
Box-and-whisker plots (center lines show the medians; box limits indicate
interquartile range; whiskers extend 1.5 times the interquartile range from
the 25th and 75th percentiles) were generated by RStudio. Student’s t test
was used to calculate statistical significance (*p < 0.05; **p < 0.01; ***p <
0.001).rs
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Figure 7. Interaction of p31comet with Either MAD2 or TRIP13 Can Promote Mitotic Exit
(A) TRIP13 forms a complex with p31comet and MAD2. FLAG-TRIP13, HA-p31comet, and HA-MAD2 were expressed in HeLa cells. Lysates were subjected to
immunoprecipitation using an antibody against FLAG. Both the total lysates and the immunoprecipitates were analyzed with immunoblotting.
(B) TRIP13 can interact with MAD2 in the absence of p31comet. FLAG-TRIP13 and HA-MAD2 were expressed in p31KO. Lysates were subjected to immuno-
precipitation using an antibody against FLAG. Both the total lysates and the immunoprecipitates were analyzed with immunoblotting. HeLa cells were also used
as a control.
(C) Lysates of TRIP13KO or TRIP13KO/p31KO re-expressing different p31comet mutants were supplemented with an ATP-regeneration system and incubated with
either buffer or bacterially expressed GST-TRIP13. After 60 min, the reactions were stopped, and MAD2 conformation was analyzed with ion exchange chro-
matography.
(D) Binding to MAD2 is critical for p31comet to inhibit MCC formation. The indicated FLAG-tagged p31comet constructs were introduced into p31KO. The cell lines
were enriched in mitosis with NOC. Lysates were prepared and subjected to immunoprecipitation using antiserum against MAD2 or CDCD20. The immuno-
precipitates and total lysates were then analyzed using immunoblotting.
(E) Binding to neither MAD2 nor TRIP13 is crucial for p31comet’s function in mitotic exit. NOC was used to synchronize p31KO expressing different p31comet
constructs in mitosis. The cells were then released into NOC-free medium and harvested for flow cytometry analysis at the indicated time points (upper). Lysates
were also prepared and analyzed with immunoblotting (lower). HeLa cells were also used as a control.
(legend continued on next page)
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